IP Library Granted Patent US 7,229,992
Granted Patent B2
US 7,229,992 · App. 10/297,592 · Granted Jun 12, 2007

Process for the preparation of a piperazine derivative

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,229,992
App. No.
10/297,592
Granted
Jun 12, 2007
Kind
B2
Abstract

(2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine dihydrochloride is obtained by debenzylating (2R)-4-benzyl-1-[3,5-bis(trifluoromethyl)-benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine, then N-alkylating and converting to hydrochloride.

Claims (18)

1. A process for preparing (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine dihydrochloride, which comprises:

(1) debenzylating (2R)-4-benzyl-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine by chemical reduction with a hydride, a combination of metals or a metal compound with an organic acid or an inorganic acid to produce (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine;

(2) reacting (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine with (2S)-4-(2-chloroethyl)-2-(methoxymethyl)morpholine or a salt thereof in the presence of a base to produce (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine; and

(3) converting the (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2 S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine to its hydrochloride salt.

2. The process of claim 1 , wherein the salt of (2S)-4-(2-chloroethyl)-2-(methoxymethyl)morpholine is an organic acid salt, an inorganic acid salt, an amino acid salt, an alkali metal salt, an alkaline earth metal salt or an ammonium salt.

3. The process of claim 1 , wherein the base of step (2) is an alkali metal carbonate, an alkali metal bicarbonate, a tri(lower)alkylamine, pyridine, an N-(lower)-alkylmorpholine, a N,N-di(lower)alkylethylamine or a N,N-di(lower)alkylbenzylamine.

4. A process for preparing (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine dihydrochloride, which comprises:

(1) debenzylating (2R)-4-benzyl-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine by reduction in the presence of a palladium catalyst and a formate salt to produce (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine;

(2) reacting (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine with (2S)-4-(2-chloroethyl)-2-(methoxymethyl)morpholine or a salt thereof in the presence of a N,N-di(lower)alkylethylamine base to produce (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine; and

(3) converting the (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine to its hydrochloride salt.

5. The process of claim 4 , wherein the temperature of the debenzylation reaction ranges from 40 to 600° C.

6. The process of claim 4 , wherein the temperature of the reaction of step (2) ranges from 40 to 60° C.

7. The process of claim 6 , wherein the reaction with base occurs in a solvent selected from the group consisting of water, an alcohol, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide or pyridine.

8. The process of claim 5 , wherein the reduction reaction occurs in a solvent selected from the group consisting of water, an alcohol, tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene chloride, chloroform, N,N-dimethylformamide or N,N-dimethylacetamide.

9. The process of claim 1 , wherein the temperature of the debenzylation reaction ranges from 40 to 60° C.

10. The process of claim 9 , wherein the reduction reaction occurs in a solvent selected from the group consisting of water, an alcohol, tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene chloride, chloroform, N,N-dimethylformamide or N,N-dimethylacetamide.

11. The process of claim 1 , wherein the temperature of the reaction of step (2) ranges from 40 to 60° C.

12. The process of claim 11 , wherein the reaction with base occurs in a solvent selected from the group consisting of water, an alcohol, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide or pyridine.

Assignments (2)
MERGER Recorded Dec 12, 2005
From: FUJISAWA PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 017073/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2005
From: KOGA, KEIICHI; ORII, RYOKI; FUJII, YOSUKE; GOTO, SHUNSUKE; HIRABAYASHI, SATOSHI
To: FUJISAWA PHARMACEUTICAL CO., LTD.
Reel/Frame 016758/0426 →